<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344067</url>
  </required_header>
  <id_info>
    <org_study_id>2015-09-002B</org_study_id>
    <nct_id>NCT04344067</nct_id>
  </id_info>
  <brief_title>Far Infrared Therapy on Peritoneal Function of CAPD Patients</brief_title>
  <acronym>CAPD</acronym>
  <official_title>The Effect of Far Infrared Therapy on Peritoneal Function of CAPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with end-stage renal disease, peritoneal dialysis (PD) has been proven to be an
      alternative choice compared to hemodialysis as a type of maintenance renal replacement
      therapy. Despite this, long-term PD is associated with structural membrane changes that are
      believed to contribute to alterations in solute transport and loss of ultrafiltration.
      Previous studies have proven that far-infrared (FIR) therapy may improve not only the
      arteriovenous fistula patency in hemodialysis patients but also abdominal discomfort due to
      encapsulating peritoneal sclerosis in PD patients. Since there is little information
      concerning this issue, this study was conducted in order to evaluate the possible effects of
      FIR therapy on the peritoneal function of patients receiving continuous ambulatory peritoneal
      dialysis (CAPD). The objective of this study is to evaluate the effect of FIR therapy on the
      peritoneal function, protein loss, and ultrafiltration capacity of CAPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 100 CAPD patients will be enrolled in this study, including 50 in treatment group
      who will receive FIR therapy for 6 months and 50 in control group. Many parameters of blood
      and urine samples as well as ultrafiltration amount, dialysate urea nitrogen, creatinine,
      Na+, K+, total protein, CA-125, and glucose degradation product (GDP) for the dialysate
      effluent of not only the first and last exchanges but also the total exchanges of daily PD
      regimen will be measured for both groups at day 1 and 6th month. However, only the FIR group
      will receive tests of blood, urine and dialysate on day 2. The significance of the study is
      that patients might benefit from the prophylactic therapeutic effects of FIR therapy, leading
      to the reduction of the hospitalization costs and the need for interventional procedures in
      CAPD patient care in Taiwan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to either the control group or the treatment (far infrared therapy) group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KT/V</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>K - dialyzer urea clearance; t - dialysis time; V - total volume within the body that urea is distributed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weekly creatinine clearance</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>WCCr (L/wk/1.73m^2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrafiltration volume</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>Peritoneal function parameter (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net volume</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>Peritoneal function parameter (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D/D0 glucose ratio</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>Peritoneal function parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D/PCr ratio</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>Peritoneal function parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D/P urea ratio</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>Peritoneal function parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>Biochemical function parameter (g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea nitrogen</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>Biochemical function parameter (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Change from baseline level at 6 months and 12 months</time_frame>
    <description>Biochemical function parameter (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular adverse events</measure>
    <time_frame>Change from baseline level at 12 months</time_frame>
    <description>3-point major adverse cardiovascular events (3P-MACE) comprising of non-fatal stroke, myocardial infarction, and cardiovascular death, coronary artery disease (CAD), hospitalized heart failure (HHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection events (number of hospital admission events)</measure>
    <time_frame>Change from baseline level at 12 months</time_frame>
    <description>Pneumonia, peritonitis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Far Infrared Therapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, the top radiator of the far infrared emitter was set at a height of 25 cm above the umbilicus with a treatment time of 40 minutes during the initial 1 hour of both the first daily and the last night-time indwelling dialysate of each daily regular peritoneal dialysis regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Far Infrared Therapy</intervention_name>
    <description>The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.</description>
    <arm_group_label>Far Infrared Therapy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic peritoneal dialysis patients who have not received any FIR therapy within the
             previous 12 months

          -  Patients on a standard continuous ambulatory peritoneal dialysis (CAPD) (1.5-2 L; 4-5
             exchanges/day) or ambulatory peritoneal dialysis (APD) program

        Exclusion Criteria:

          -  History of CAPD-related peritonitis within 3 months prior to the study period;

          -  History of cerebrovascular accident or myocardial infarction or interventional
             procedure (percutaneous transluminal coronary angioplasty or stent) for coronary
             artery disease within the 3 months prior to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Ching Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Ching Lin, MD, PhD</last_name>
      <phone>02-2871-2121</phone>
      <phone_ext>2993</phone_ext>
      <email>lincc2@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Chih-Ching Lin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. J Am Soc Nephrol. 2007 Mar;18(3):985-92. Epub 2007 Jan 31.</citation>
    <PMID>17267744</PMID>
  </reference>
  <reference>
    <citation>Lin CC, Liu XM, Peyton K, Wang H, Yang WC, Lin SJ, Durante W. Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):739-45. doi: 10.1161/ATVBAHA.107.160085. Epub 2008 Jan 17.</citation>
    <PMID>18202320</PMID>
  </reference>
  <reference>
    <citation>Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. Am J Kidney Dis. 2013 Aug;62(2):304-11. doi: 10.1053/j.ajkd.2013.01.015. Epub 2013 Mar 6.</citation>
    <PMID>23474008</PMID>
  </reference>
  <reference>
    <citation>Lin CC, Chung MY, Yang WC, Lin SJ, Lee PC. Length polymorphisms of heme oxygenase-1 determine the effect of far-infrared therapy on the function of arteriovenous fistula in hemodialysis patients: a novel physicogenomic study. Nephrol Dial Transplant. 2013 May;28(5):1284-93. doi: 10.1093/ndt/gfs608. Epub 2013 Jan 22.</citation>
    <PMID>23345623</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Far Infrared Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

